With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Vaxcyte, Inc. (($PCVX)) announced an update on their ongoing clinical study. Vaxcyte, Inc. is conducting a Phase 2 clinical study titled ‘A Phase ...

A series of recommended shots that health providers administer to children as they age has been a recent target of President Donald Trump and his administration.

Eligibility for this vaccination is suddenly a timely question. A senior health editor reports on her real-time experience.

Pneumococcal disease poses a severe risk to Indian adults, particularly those with chronic health issues. Despite effective ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...

Electronic medical records of 42 children with SCD diagnosed between 2009 and 2023 were retrospectively reviewed. Clinical demographic data and pneumococcal serologies were analysed. Of the 42 ...

Infectious disease researchers found the vaccine, used to prevent herpes zoster, or shingles, is also linked to lower risks ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...

The shingles vaccine may cut dementia risk by up to 33%, per new research. Here, experts explain how it works and what it may mean for brain health.

In addition to the flu vaccine, the recently updated COVID-19 vaccine and the RSV vaccine are available, as well as vaccines ...